-

Kaskela Law Firm Announces Investigation of Agilon Health, Inc. (AGL) and Encourages Long-Term AGL Shareholders with Investment Losses to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Agilon Health, Inc. (NYSE: AGL) (“Agilon”) on behalf of the company’s long-term investors.

The investigation seeks to determine whether the members of Agilon’s board of directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct.

Share

Click here for additional information: https://kaskelalaw.com/case/agilon-health/

Recently a securities fraud complaint was filed against Agilon on behalf of certain investors who purchased shares of the company’s stock between April 15, 2021 and February 27, 2024. According to the complaint, during that time period Agilon and several of the company’s senior executive officers made a series of materially false and misleading statements to investors about Agilon’s medical costs.

As further detailed in the complaint, as the true information about the company’s higher medical costs was disclosed to the market, shares of the company’s stock significantly declined in value, harming the company’s long-term investors. Specifically, Agilon’s stock declined from a trading price of over $44.00 per share to less than $6.50 per share (prior to the company’s March 2026 1-for-25 reverse stock split), a decline of approximately 85% in value.

The investigation seeks to determine whether the members of Agilon’s board of directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct.

Current Agilon shareholders who purchased or acquired their AGL shares prior to May 1, 2023 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information about this investigation and their legal rights and options at (484) 229 – 0750, by email at abell@kaskelalaw.com, or online at:

https://kaskelalaw.com/case/agilon-health/

ABOUT KASKELA LAW:

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis (i.e., the firm’s clients are never responsible for any out-of-pocket costs for legal representation). Since 2020, the firm has helped to recover over $500 million for investors. For additional information about Kaskela Law LLC, including the firm’s recent notable recoveries for investors, please visit www.kaskelalaw.com.

This communication may constitute attorney advertising in certain jurisdictions.

Contacts

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
(skaskela@kaskelalaw.com)
Adrienne Bell, Esq.
(abell@kaskelalaw.com)
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 229 - 0750
www.kaskelalaw.com

Kaskela Law LLC

NYSE:AGL

Release Versions

Contacts

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
(skaskela@kaskelalaw.com)
Adrienne Bell, Esq.
(abell@kaskelalaw.com)
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 229 - 0750
www.kaskelalaw.com

More News From Kaskela Law LLC

Kaskela Law Firm Announces Investigation of DexCom, Inc. (DXCM) and Encourages Long-Term DXCM Shareholders with Investment Losses to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating DexCom, Inc. (Nasdaq: DXCM) on behalf of the company’s long-term investors. Click here for additional information: https://kaskelalaw.com/case/dexcom-inc/ Recently a securities fraud complaint was filed against DexCom on behalf of investors who purchased shares of the company's stock between January 8, 2024 and September 17, 2025 (the “Wrongdoing Period”). According to the complaint, during th...

Kaskela Law Firm Announces Investigation of Fortrea Holdings Inc. (FTRE) and Encourages Long-Term FTRE Shareholders with Investment Losses to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Fortrea Holdings Inc. (Nasdaq: FTRE) (“Fortrea”) on behalf of the company’s long-term investors. Click here for additional information: https://kaskelalaw.com/case/fortrea-holdings/ Recently a securities fraud complaint was filed against Fortrea on behalf of certain investors who purchased shares of the company’s stock between July 5, 2023 and February 28, 2025 (the “Wrongdoing Period”). Accor...

Kaskela Law Firm Announces Investigation of PACS Group, Inc. (PACS) and Encourages Long-Term PACS Shareholders to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating PACS Group, Inc. (NYSE: PACS) (“PACS”) on behalf of the company’s long-term investors. Click here for additional information: https://kaskelalaw.com/case/pacs-group/ Recently a federal securities fraud complaint was filed against PACS on behalf of certain investors who purchased shares of the company’s stock between April 11, 2024 and December 16, 2024 (the “Wrongdoing Period”). According to t...
Back to Newsroom